Plain-English translation of NCT07111494 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether glucagon-like peptide-1 (GLP-1) analogs—medications commonly used to treat type 2 diabetes and support weight loss—might also help reduce joint pain and inflammation in people with psoriatic arthritis. The study will compare this medication to nutrition counseling alone to see which approach works better for people who have psoriatic arthritis along with obesity and diabetes.
Many people with psoriatic arthritis also struggle with weight and diabetes, and current treatments don't work well enough for everyone. Researchers want to know if this medication, which already helps with blood sugar and weight, might also calm the joint inflammation that makes psoriatic arthritis painful.
You likely qualify if…
You likely don't qualify if…
If you join, you'll be randomly assigned to either take the medication or receive nutrition counseling for 24 weeks. You'll visit the study center about four times during this period. At each visit, you'll complete questionnaires about how you're feeling, have a physical exam, and have your blood drawn. The researchers will track changes in your joint pain, swelling, and overall health to see which approach helps most.
AI-generated summary from trial data · Aug 12, 2026 · Not medical advice
United States